Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Nivolumab and ipilimumab for advanced BCVH

Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Phase II study (NCT03333616) looking at nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.